Atyr PHARMA (NASDAQ:ATYR) Upgraded by Leerink Partnrs to “Strong-Buy” Rating

Leerink Partnrs upgraded shares of Atyr PHARMA (NASDAQ:ATYR) to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

Several other research firms have also weighed in on ATYR. Leerink Partners initiated coverage on Atyr PHARMA in a report on Tuesday. They set an “outperform” rating and a $16.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Atyr PHARMA in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald initiated coverage on Atyr PHARMA in a research note on Monday, January 6th. They set an “overweight” rating for the company. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $18.60.

Atyr PHARMA Trading Up 11.1 %

Shares of NASDAQ ATYR opened at $3.79 on Tuesday. Atyr PHARMA has a twelve month low of $1.42 and a twelve month high of $4.22. The stock has a market cap of $318.13 million, a price-to-earnings ratio of -4.03 and a beta of 1.10. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The company’s fifty day moving average is $3.55 and its 200-day moving average is $2.83.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of Atyr PHARMA by 52.0% in the third quarter. JPMorgan Chase & Co. now owns 31,440 shares of the company’s stock valued at $55,000 after purchasing an additional 10,754 shares during the last quarter. Alterna Wealth Management Inc. acquired a new position in Atyr PHARMA during the fourth quarter worth $36,000. Kingswood Wealth Advisors LLC bought a new position in Atyr PHARMA in the fourth quarter valued at $170,000. American Century Companies Inc. acquired a new stake in Atyr PHARMA in the 4th quarter valued at $319,000. Finally, Raymond James Financial Inc. bought a new stake in Atyr PHARMA during the 4th quarter worth about $39,000. 61.72% of the stock is owned by institutional investors and hedge funds.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.